E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial.

Autor: Bewersdorf JP; Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stahl M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Taylor J; Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Mi X; Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chandhok NS; Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Watts J; Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Derkach A; Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wysocki M; Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lu SX; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bourcier J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hogg SJ; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rahman J; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chaudhry S; Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Totiger TM; Leukemia Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Abdel-Wahab O; Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org.; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA. abdelwao@mskcc.org., Stein EM; Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. steine@mskcc.org.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2023 Dec; Vol. 37 (12), pp. 2512-2516. Date of Electronic Publication: 2023 Oct 09.
DOI: 10.1038/s41375-023-02050-4
Databáze: MEDLINE
Externí odkaz: